.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
In a significant move within the Indian healthcare sector, the 360 ONE Asset management firm is set to facilitate a major hospital stake buyback. Specifically, they will lend approximately ₹600 crore to Narendra Pandey, the founder of the Asian Institute of Medical Sciences (AIMS). This funding enables the repurchase of a 49% stake currently held by British International Investment and OrbiMed. Consequently, Pandey will consolidate his ownership of the Faridabad-based 450-bed hospital. This transaction highlights the growing reliance on private credit for ownership consolidation in India.
The deal values the hospital at around ₹1,200 crore. Previously, the private equity investors attempted to sell their stakes to other firms. However, those efforts failed due to high valuation expectations. Therefore, Pandey chose to explore structured credit solutions to regain control. This trend is becoming increasingly common among Indian promoters. Furthermore, the healthcare delivery sector remains robust, with standalone hospitals often fetching high valuations based on earnings. As a result, founders are keen to maintain their equity before potentially pursuing public listings.
Consolidation of ownership allows founders to maintain their long-term vision for clinical excellence. In particular, the AIMS founder's decision reflects confidence in the hospital's growth potential. Private credit platforms like 360 ONE now play a pivotal role in such transactions. Additionally, this shift indicates a maturing financial ecosystem for Indian healthcare providers. Moreover, many companies with IPO ambitions prefer this route to streamline their capital structure. Lastly, we are seeing more structured debt deals across various sectors in India.
Q1: Who is financing the AIMS stake buyback?
360 ONE Asset is expected to lend about ₹600 crore to facilitate the transaction for the AIMS founder.
Q2: What is the estimated valuation of AIMS hospital in this deal?
The 450-bed multispecialty hospital is expected to be valued at approximately ₹1,200 crore.
Q3: Why did the previous sale of the stake fail?
Previous attempts to sell the stake to other private equity investors reportedly failed due to high valuation expectations from the sellers.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Narendra Pandey, founder of AIMS, is set to repurchase a 49% stake from PE investors with ₹600 crore in funding from 360 ONE Asset management firm....
6 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
